CMV Prophylaxis and Infection
Cytomegalovirus (CMV) is the most common serious viral infection affecting kidney transplant recipients. It may present as a nonspecific febrile illness (fever, leukopenia) or as tissue-invasive disease such as hepatitis, pneumonitis, or enteritis.
- Risk Stratification
The risk of developing CMV is primarily determined by the donor (D) and recipient (R) serological status at the time of transplant:
- High Risk (D+/R–):
CMV-naive recipients receiving a kidney from a CMV-positive donor have the highest risk for severe disease. - Moderate Risk (D+/R+ or D–/R+):
Seropositive recipients are at risk due to reactivation of latent CMV or infection with a new viral strain. - Low Risk (D–/R–):
Incidence is below 5%, and routine prophylaxis is generally not required. - Clinical Risk Factors:
Use of T-cell (lymphocyte) depleting antibodies for induction or rejection treatment significantly increases CMV risk.
- Prophylaxis Strategies
Prophylaxis involves routine antiviral therapy to prevent CMV infection.
- Recommended Medications:
Valganciclovir is the first-line agent; oral ganciclovir and valaciclovir are also effective alternatives. - Standard Duration:
Prophylaxis should continue for 3–6 months post-transplant, or until immunosuppression is reduced to long-term maintenance levels. - After Rejection Treatment:
Recipients treated with a T-cell depleting antibody for acute rejection should receive an additional 6 weeks of antiviral prophylaxis. - Monitoring After Prophylaxis:
Because “late CMV” can occur after stopping prophylaxis, patients should be monitored clinically and virologically for at least 3 months after completing therapy.
- Treatment of CMV Infection
When active infection is confirmed by plasma NAT, the following treatments are recommended:
- Serious or Life-Threatening Disease:
Intravenous (IV) ganciclovir is the first-line treatment. - Mild to Moderate Disease (Adults):
Oral valganciclovir and IV ganciclovir have equivalent efficacy for non-severe cases. - Pediatric Recipients:
All CMV disease in children should be treated with IV ganciclovir. - Duration of Therapy:
Treatment continues until symptoms resolve and viral load becomes undetectable by plasma NAT. - Immunosuppression Adjustment:
In severe or persistent cases, maintenance immunosuppression should be reduced until the infection is controlled.
- Clinical Monitoring
Transplant units should have a written CMV management strategy, which may include universal prophylaxis for at-risk patients or a pre-emptive approach (monitoring viral loads and treating when a threshold is reached).
During active CMV disease, viral loads should be checked weekly to assess treatment response and detect potential antiviral resistance.
